JP6294456B2 - 修飾されたドセタキセルリポソーム製剤 - Google Patents

修飾されたドセタキセルリポソーム製剤 Download PDF

Info

Publication number
JP6294456B2
JP6294456B2 JP2016502155A JP2016502155A JP6294456B2 JP 6294456 B2 JP6294456 B2 JP 6294456B2 JP 2016502155 A JP2016502155 A JP 2016502155A JP 2016502155 A JP2016502155 A JP 2016502155A JP 6294456 B2 JP6294456 B2 JP 6294456B2
Authority
JP
Japan
Prior art keywords
lipid
peg
liposome
mol
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513655A (ja
Inventor
ウィリアム マッギー，
ウィリアム マッギー，
ジェイムズ ブラックレッジ，
ジェイムズ ブラックレッジ，
マーガレット グラパーハウス，
マーガレット グラパーハウス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2016513655A publication Critical patent/JP2016513655A/ja
Application granted granted Critical
Publication of JP6294456B2 publication Critical patent/JP6294456B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016502155A 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤 Expired - Fee Related JP6294456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779902P 2013-03-13 2013-03-13
US61/779,902 2013-03-13
PCT/US2014/026483 WO2014160392A1 (en) 2013-03-13 2014-03-13 Modified docetaxel liposome formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017177620A Division JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤

Publications (2)

Publication Number Publication Date
JP2016513655A JP2016513655A (ja) 2016-05-16
JP6294456B2 true JP6294456B2 (ja) 2018-03-14

Family

ID=50686145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502155A Expired - Fee Related JP6294456B2 (ja) 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤
JP2018173770A Pending JP2019006815A (ja) 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤
JP2018173770A Pending JP2019006815A (ja) 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤

Country Status (8)

Country Link
US (1) US20140271822A1 (enExample)
EP (1) EP2968145A1 (enExample)
JP (3) JP6294456B2 (enExample)
CN (1) CN105188675A (enExample)
BR (1) BR112015022819A8 (enExample)
CA (1) CA2903255C (enExample)
MX (1) MX2015012201A (enExample)
WO (1) WO2014160392A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968145A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
CN104622810B (zh) * 2015-02-15 2018-06-08 中国药科大学 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
WO2016161428A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York Serum-stable compositions and methods for light-triggered release of materials
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
PH12022550592A1 (en) * 2016-01-07 2023-07-17 Tesorx Pharma Llc Formulations for treating bladder cancer
BR112018068000A2 (pt) * 2016-03-16 2019-02-05 Merrimack Pharmaceuticals Inc composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2)
EP3429631A1 (en) * 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
JP2019512477A (ja) * 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
KR102509892B1 (ko) * 2016-08-18 2023-03-13 트로이 브레머 리포솜 작제물을 사용한 황반 및 망막의 세포에의 우레아의 전달
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
US20210290537A1 (en) * 2016-12-08 2021-09-23 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
CA3069125A1 (en) 2017-07-07 2019-01-10 Drexel University Voltage-activated therapeutic, diagnostic, and/or theranostic constructs
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
EP3866764A4 (en) * 2018-10-17 2022-07-13 Taiwan Liposome Company, Ltd. DELAYED RELEASE PHARMACEUTICAL COMPOSITIONS WITH AN IMMUNOMODULATING AGENT AND USES THEREOF
AR122300A1 (es) * 2019-08-09 2022-08-31 Tesorxpharma Llc Formulaciones proliposomales de testosterona undecanoato
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114588279B (zh) * 2022-03-31 2023-10-20 重庆医科大学附属第二医院 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用
WO2025124498A1 (zh) * 2023-12-13 2025-06-19 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物的脂质体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7985417B2 (en) * 2004-10-08 2011-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of lipid structure preparation
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
JP5542804B2 (ja) * 2008-05-23 2014-07-09 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア リポソームナノ粒子中で使用するための修飾薬物
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
EP2667848A1 (en) * 2011-01-28 2013-12-04 Koninklijke Philips N.V. Carriers for the local release of hydrophilic prodrugs
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
EP2968145A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations

Also Published As

Publication number Publication date
MX2015012201A (es) 2015-11-30
US20140271822A1 (en) 2014-09-18
JP2019006815A (ja) 2019-01-17
JP2016513655A (ja) 2016-05-16
WO2014160392A1 (en) 2014-10-02
BR112015022819A8 (pt) 2019-11-26
EP2968145A1 (en) 2016-01-20
CN105188675A (zh) 2015-12-23
CA2903255C (en) 2018-08-28
JP2017214433A (ja) 2017-12-07
BR112015022819A2 (pt) 2017-07-18
CA2903255A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
JP2019006815A (ja) 修飾されたドセタキセルリポソーム製剤
JP6549172B2 (ja) がん治療用組合せリポソーム組成物
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
US20120082616A1 (en) Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers
JP2014527071A (ja) Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変
US20130183236A1 (en) Mmp-targeted therapeutic and/or diagnostic nanocarriers
US20160250177A1 (en) Modified docetaxel liposome formulations and uses thereof
US20200079785A1 (en) Mitomycin c prodrug liposome formulations and uses thereof
US20210290537A1 (en) Liposomal elinafide formulations and uses thereof
Nardo et al. In vivo assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180215

R150 Certificate of patent or registration of utility model

Ref document number: 6294456

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees